

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Sheet 1 of 3

Complete if Known

Application Number	PHARMA-123
Filing Date	October 15, 2001
First Named Inventor	BOULOUS ZACHARIE et al.
Group Art Unit	1848 1654
Examiner Name	Unassigned
Attorney Docket Number	PHARMA-123

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	1	M.P.. DI MARCO ET AL., <u>Journal of Chromatography</u> , 645, (1993) 107-114 Elsevier Science Publishers, B.V. Amsterdam, "High-performance liquid chromatographic determination of the isomeric purity of a series of dioxolane nucleoside analogues".	
	2	HAOLUN JIN ET AL. <u>Tetrahedron Asymmetry</u> Vol. 4, No. 2 pp 211-214, 1993, "Unexpected Effects of Lewis Acids in the Synthesis of Optically Pure 2'-Deoxy-3'-oxacytidine Nucleoside Analogues"	
	3	COLLEEN A. EVANS ET AL. <u>Tetrahedron: Asymmetry</u> Vol. 4, No. 11, pp. 2319-2322, 1993 "Divergent Asymmetric Syntheses of Dioxolane Nucleoside Analogues"	
	4	ARSHAD SIDDIQUI ET AL., <u>Bioorganic & Medicinal Chemistry</u> , Vol. 3, No. 8, pp. 1543-1546, 1993, "Antiviral Optically Pure Dioxolane Purine Nucleosides Analogues"	
	5	BERNARD R. BELLEAU ET AL., <u>Tetrahedron Letters</u> , Vol. 33, No. 46, pp. 6949-6952, 1992 "Oxidative Degradation of L-Ascorbic Acid Acetals to 2',3'-Dideoxy-3'-Oxaribofuranosides. Synthesis of Enantiomerically Pure 2',3'-Dideoxy-3'-Oxacytidine Stereoisomers as Potential Antiviral Agents"	
	6	HEA O. KIM ET AL., <u>Tetrahedron Letters</u> , Vol. 33, No. 46, pp. 6899-6902, 1992, "Potent Anti-HIV and Anti-HBV Activities (-)-L-β-Dioxolane-C and (+)-L-β-Dioxolane-T and Their Asymmetric Syntheses	
	7	JOHN R. MACKEY ET AL., <u>Cancer Research</u> , 58, 4349-4357, October 1, 1998 "Functional Nucleoside Transporters Are Required for Gemcitabine Influx and Manifestation of Toxicity in Cancer Cell Lines"	
	8	KRISTIE L. GROVE AND UUNG-CHI CHENG, <u>Cancer Research</u> , 56, 4187-4191, September 15, 1996, "Uptake and Metabolism of the New Anticancer Compound β-L-()-Dioxolane-Cytidine in Human Prostate Carcinoma DU-145 Cells"	
	9	US Patent 5,041,449, Belleau et al.	
	10	US Patent 5,817,667, Chu et al.	
	11	WENDY P. GATI AND ALAN R. P. PATERSON, <u>The American Society for Pharmacology and Experimental Therapeutics</u> , Molecular Pharmacology, 36:134-141, "Interaction of (3H) Dilazep at Nucleoside Transporter-Associated Binding Sites on S49 Mouse Lymphoma Cells"	



RECEIVED
 MAY 08 2002
 TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Compl te If Known

Application Number	PHARMA-123
Filing Date	Oct ber 15, 2001
First Named Inventor	BOULOUS ZACHARIE et al.
Group Art Unit	4816 1654
Examiner Name	Unassigned
Attorney Docket Number	PHARMA-123

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	12	Proc. Amer. Assoc. Cancer Res. 37:405 (1996), "Use of SAENTA-fluorescein in a flow cytometric assay of cellular es nucleoside transporter site abundance, a correlate of chemosensitivity to cytarabine in acute myeloid leukemia cells"	
	13	KATHRYN A. GRAHAM ET AL., <u>Nucleosides, Nucleotides & Nucleic Acids</u> , (19(1&2), 415-434 (2000), "Differential Transport of Cytosine-Containing Nucleosides by Recombinant Human Concentrative Nucleoside Transporter Protein hCNT1."	
	14	ERIC R. HARLEY ET AL., <u>Cancer Research</u> , 42, 1289-1295, April 1982, "Initial Rate Kinetics of the Transport of Adenosine and 4-Amino-7-(β-D-ribofuranosyl) pyrrolo(2,3-d) pyrimidine (Tubercidin) in Cultured Cells"	
	15	CHARLES R. CRAWFORD ET AL., <u>Biochimica et Biophysica Acta</u> , 1024 (1990) 289-297, "Identification and reconstitution of the nucleoside transporter of CEM human leukemia cells"	
	16	MABEL W. L. RITZEL ET AL., <u>Molecular Membrane Biology</u> , 1998, 15, 203-211, "Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na ⁺ /nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine"	
	17	MABEL W. L. RITZEL ET AL., <u>American Physiulogical Society</u> 0363-6143/97, "Molecular cloning and functional expression of cDNAs encoding a human Na ⁺ -nucleoside cotransporter (hCNT1)"	
	18	BUDDY ULLMAN, <u>J. Physiol (Lord)</u> 1989 (Sept), 601:416-421, "Dideoxycytidine Metabolism in Wild Type and Mutant Cem Cells Deficient in Nucleoside Transport or Deoxycytidine Kinase"	
	19	HARALABIA BOLETI ET AL., <u>Neuropharmacology</u> , Vol. 36, No. 9, pp. 1167-1179, 1997, "Molecular Identification of the Equilibrative NBMPR-sensitive (es) Nucleoside Transporter and Demonstration of an Equilibrative NBMPR-insensitive (ei) Transport Activity in Human Erythroleukemia (K562) Cells"	
	20	CHRISTINE E. BOUMAH, DOUGLAS L. HOGUE AND CAROL E. CASS, <u>BioChem J.</u> (1992, 288, 987-996, "Expression of high levels of nitrobenzylthioinosine sensitive nucleoside transport in cultured human choriocarcinoma (BeWo) cells"	

O I P E
MAY 07 2002
TRADEMARK OFFICE

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Application Number		PHARMA-123	
Filing Date		Oct ber 15, 2001	
First Named Inventor		BOULOUS ZACHARIE et al.	
Group Art Unit		4848 1654	
Examiner Name		Unassigned	
Attorney Docket Number		PHARMA-123	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<div style="border: 1px solid black; border-radius: 50%; padding: 10px; display: inline-block;"> O I P E MAY 07 2002 TRADEMARK OFFICE </div>	21	XIAO FANG ET AL., <u>Biochem J. (1996) 317, 457-465</u> , "Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity of pyrimidine nucleosides (cNT1) by transient expression in cultured mammalian cells"	
	22	WENDY P. GATI ET AL., <u>Biochem J. (1989) 263, 957-960</u> , "Enantiomeric selectivity of adenosine transport systems in mouse erythrocytes and L1210 cells"	
	23	DOUGLAS L. HOGUE ET AL, <u>Biochem. Cell. Biol. Vol. 68, 1990</u> , "Effects of inhibitoin of N-linked glycosylation by tunicamycin on nucleoside transport polypeptides of L1210 leukemia cells"	
	24	JOHN R. MACKEY ET AL., <u>Cancer Research 58, 4349-4357, October 1, 1998</u> , "Functional Nucleoside Transporters Are Required for Gemcitabine Influx and Manifestation of Toxicity in Cancer Cell Lines"	
	25	ALAN R. P. PATERSON ET AL., <u>1991 Elsevier Science Publishers BV, Chapter 13</u> , "Plasma Membrane Transport of Nucleosides, Nucleobases and Nucleotides: an overview"	
	26	BUDDY ULLMAN ET AL, <u>The Journal of biological Chemistry, Vol. 263, No. 25, Issue of September 5, pp. 12391-12396, 1988</u> , "Genetic Analysis of 2',3'-Dideoxycytidine Incorporation into Cultured Human T Lymphoblasts"	
	27	JOANNE M. UPSTON, ANNETTE M. GERO, <u>Biochimica et Biophysica Acta 1236 (1995) 249-258</u> , "Parasite-induced permeation of nucleosides in <i>Plasmodium falciparum</i> , malaria"	
	28	MACKEY ET AL., <u>Drug Resistance Updates, (1998) I, 310-324</u> , "Nucleoside transport and its significance for anticancer drug resistance"	

Examiner Signature		Date Considered	11/15/04
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
MAY 08 2002
TECHNICAL CENTER 1600/2900

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/876,249
		Filing Date	October 15, 2001
		First Named Inventor	Giorgio ATTARDO
		Group Art Unit	1654
		Examiner Name	Michael V. Meller
		Attorney Docket Number	PHARMA-123
Sheet	1	of	2

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature		Date Considered	6/2/03
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>2</u> of <u>2</u>		Complete If Known	
		Application Number	09/876,249
		Filing Date	October 15, 2001
		First Named Inventor	Giorgio ATTARDO
		Group Art Unit	1654
		Examiner Name	Michael V. Meller
		Attorney Docket Number	PHARMA-123

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AMM	4	K.L. Grove et al, "Beta-L-(-)-Dioxolane Cytidine As A Potent Compound For The Treatment Of Cancer", Nucleosides & Nucleotides, Vol. 16, No. 7-9, 1997, pp. 1229-33, XP000971189	
	5	S.A. Kadhim et al, "Potant Antitumor Activity Of A Novel Nucleoside Analogue", Cancer Research, Vol. 57, November 1, 1997, pp. 4803-4810, XP000971188	
	6	Chemical Abstracts, Vol. 133, No. 5, 2000, Columbus, Ohio, US; abstract no. 53116p, Kukhanova, M.: "Excision Of Beta-L-And Beta-D-Nucleotide Analogs From DNA By P53 Protein", pg. 17; column 1; XP002199460, abstract & Nucleosides, Nucleotides Nucleic Acids, Vol. 18; No. 1-2, 2000, pp. 435-448, USA	
	7	K. Grove et al, "Anticancer Activity Of Beta-L-Dioxolane-Cytidine", Cancer Research, Vol. 55, July 15, 1995, pp. 3008-11, XP002199458, American Association For Cancer Research, Baltimore, MD., US	
	8	S.A. Rabbani et al, "Effect of Nucleoside Analogue BCH-4558 On Prostate Cancer Growth And Metastases", Cancer Research, Vol. 58, August 1, 1998, pp. 3481-5, XP002199459, American Association For Cancer Research, Baltimore, MD, US	

Examiner Signature

Date Considered

6/2/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.